1. Buy Geftinat 250mg Online

Geftinat 250 mg Tablet is an anticancer medicine which is used in the treatment of cancer of the lungs. It should only be used under the supervision of a qualified physician. This medicine is not recommended for use in patients with lung and liver diseases.

Gefitinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer.

Gefitinib may also be prescribed for other conditions as determined by the doctor.

2. How To Geftinat 250mg Work?

Geftinat tablets 250mg contain gefitinib a potent inhibitor of tyrosine kinase (TK), an enzyme that phosphorylates a protein inside a cell (transfers a phosphate from ATP to a protein inside the cell), which is the way many cell processes are regulated.

Tyrosine kinases (TK) are cell surface receptors for many cellular messengers including growth factors and gefitinib in Geftinat tablets 250mg acts as a potent inhibitor of the Epidermal Growth Factor receptor (EGFR) by targeting the part of the receptor where EGF binds to ATP (adenosine triphosphate).

EGF stimulates cell growth, proliferation and differentiation in normal cells. It acts by binding with high affinity to its cell surface receptor EGFR, which belongs to the TK family of receptors.

When EGF binds to EGFR, the receptor undergoes a shape change, which activates TK activity by phosphorylation of its substrates within the cell and this is the first step in a complex cell signalling pathway involved in cell proliferation and survival. Normally EGFR activation is regulated and therefore, cell proliferation is controlled and programmed cell death (apoptosis) takes place.

However, the mutation associated with NSCLC leaves the receptor in a state that is constantly activated or turned on (constitutively activated) even when EGF is not bound to the receptor. This results in cells that are stimulated to constantly proliferate and survive leading to NSCLC.

Normally the expression of ECGFR is expressed at low levels but over expression can cause cancer and is associated with aggressive advanced and metastatic tumours as is found in 40-80% of NSCLC4.

There are several different gene mutations that can affect the control of EGFR activity and gefitinib in Geftinat tablets 250mg is most effective in tumours containing the Exon 19 deletion or a L858R mutation, which is point mutations affecting a single DNA nucleotide. It has been suggested that identification of specific mutations in the ECGFR gene may predict sensitivity to gefitinib5, 6.

There is also evidence of amplification of the specific mutated activating gene in some cases of NSCLC and this is thought to confer increased susceptibility to gefitinib in Geftinat tablets 250mg1. Gefitinib in Geftinat tablets 250mg works by blocking the intracellular phosphorylation of EGFR, which blocks the signalling pathway for cell proliferation and survival and induces cell death in NSCLC cells, which results in tumour regression.

3. How To Take Geftinat 250mg Tablet?

You should take your Geftinat tablets 250mg swallowed whole with a glass of water once daily with or without food. The dose you take and for how long depends on your doctor’s recommendation and you should continue to take your Geftinat tablets 250mg for as long as recommended by your doctor.

4. Drug interaction of Geftinat 250mg

Interaction with Alcohol

Description - Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions - Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Interaction with Medicine

The drugs that interact with Gefitinib are:

Acetaminophen

Carbamazepine

Chloramphenicol

Cimetidine

Ciprofloxacin

Clarithromycin

Indinavir

Ketoconazole

Leflunomide

Lomitapide

Mipomersen

Omeprazole

Ranitidine

Warfarin

5. Side Effects of Geftinat 250mg

Abdominal pain

Diarrhoea

Fatigue

Fever

Headache

Loss of appetite

Eye irritation

Blurred vision

Clay-coloured stools

Discolouration of urine

Skin rash

6. Warning of Geftinat 250mg tablet

Skin reactions - Patients receiving Geftinat 250 mg Tablet have experienced severe skin reactions like toxic epidermal necrolysis, Stevens Johnson syndrome, and erythema multiforme. Close monitoring of symptoms like change in color of the skin, skin rashes, itching, blistering, etc. is necessary while receiving this medicine. Any such symptoms should be reported to the doctor on priority. The treatment should be discontinued if these symptoms appear.

Pregnancy - This medicine is not recommended for use in pregnant women.

Breast-feeding - This medicine is not recommended for use in breastfeeding women unless absolutely necessary. If this medicine is prescribed, your doctor will advise you to discontinue breastfeeding.

7. Precaution of Geftinat 250mg tablet

are allergic to gefitinib or any ingredients in Geftinat

are pregnant or are breastfeeding

have kidney or liver disease

have a history of eye pain or inflammation

have gastrointestinal problems particularly diarrhoea as this can worsen with Geftinat

have lung problems like pneumonia or interstitial lung disease

are taking medicines that interact with Geftinat, including corticosteroids and NSAIDs for pain and inflammation, anticoagulants like warfarin, the beta blocker metoprolol, verapamil for hypertension, proton pump inhibitors like omeprazole, antifungals like ketoconazole, antibiotics like ciprofloxacin, erythromycin, clarithromycin, rifampicin, anticonvulsants like phenytoin, carbamazepine, ranitidine for reflux.

If you have an allergy to gefitinib or any other part of this drug. Tell your doctor if you are allergic to any drugs. Make sure to tell about the allergy and what signs you had. This includes telling about rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs. If you are pregnant or may be pregnant. If you are breast-feeding.

8. Uses of Geftinat 250mg

Geftinat tablets 250mg are used as first line therapy to treat locally advanced (stage III) or metastatic (stage IV) non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and grows more slowly than small cell lung cancer (SCLC). NSCLC is associated with a mutation in the gene for Epidermal Growth Factor Receptor (EGFR) in a proportion of these cancers1, 2 specifically those with a cell type of adenocarcinoma3. Epidermal Growth Factor is a growth factor that is found in many normal tissues and controls cell growth. However, in some types of cancer including NSLC, its action is uncontrolled, allowing cells to continue to grow and spread. For Geftinat tablets 250mg to be an effective treatment for NSCLC a specific type of gene mutation should be identified and present in the tumour cells. In these cases of treatment of NSCLC with Geftinat tablets 250mg is highly effective in preventing disease progression.

9. Storage of Geftinat 250mg

Store Geftinat tablet at controlled room temperature (59°F to 86°F, 15°C to 30°C). Protect from light. Protect from moisture.